KR-12 Human Antimicrobial Peptide: Mechanism

Executive Summary. KR-12 is the 12-residue LL-37 fragment KRIVQRIKDFLR, corresponding to amino acids 18–29 of human cathelicidin LL-37 product information. The supplied material is a trifluoroacetate salt with a molecular weight of 1684.97 Da and a recommended storage temperature of −20 °C product specifications. The peptide targets bacterial anionic membranes and is described as causing lipid clustering and membrane perforation mechanistic product description. A 2024 study identified Asp26 and Arg29 as important contributors to Cu(II) interaction, while also implicating peptide-backbone oxygen atoms Brzeski, Wyrzykowski, and Makowska, 2024.

Biological Rationale

LL-37 is the only human cathelicidin described in the cited Dalton Transactions study. It is a cationic antimicrobial protein that contributes to innate host defense 2024 reference study. Cationic residues promote electrostatic attraction to negatively charged microbial surfaces. KR-12 retains a compact sequence rich in lysine and arginine residues, including the sequence KRIVQRIKDFLR product information.

The fragment was identified as the smallest antibacterial peptide derived from LL-37 in the cited literature. The same study distinguishes KR-12 from longer LL-37-derived fragments that can retain mammalian cytotoxicity under tested conditions 2024 reference study. This distinction matters for experimental design. A short peptide can preserve a membrane-active pharmacophore without reproducing every structural and biological property of full-length LL-37.

KR-12 should therefore be treated as a defined mechanistic probe rather than as a universal substitute for antibiotics. Its reported spectrum includes selected Gram-negative bacteria, Gram-positive bacteria, yeast, and multidrug-resistant isolates, but the listed results do not establish broad-spectrum activity product information.

Mechanism of Action of KR-12 (human) TFA

Membrane association and disruption

The primary proposed mechanism is interaction with bacterial anionic membranes. Positively charged residues can concentrate the peptide at negatively charged phospholipid or lipopolysaccharide-rich surfaces. The product description attributes activity to membrane-structure disruption through lipid clustering and membrane perforation mechanistic product description.

These terms describe a membrane-level model, not a guarantee of identical pore formation in every organism. Membrane composition, surface charge, peptide aggregation, ionic strength, and assay format can alter apparent potency. Consequently, a minimum inhibitory concentration should be interpreted together with the strain, medium, inoculum, incubation conditions, and endpoint definition.

Cu(II) coordination

The 2024 Dalton Transactions paper combined theoretical analysis with potentiometric titration and isothermal titration calorimetry. Its GFN2-xTB/ALPB analysis indicated that KR-12 interacts with Cu(II) mainly through peptide-backbone oxygen atoms. The study identified aspartate and Arg29 as important residues in favorable coordination models Brzeski, Wyrzykowski, and Makowska, 2024.

For the product sequence, the aspartate residue is Asp26. Cu(II) binding may influence peptide conformation, charge distribution, or membrane interaction, but the cited study does not establish that copper binding improves antimicrobial efficacy in a biological infection model 2024 reference study. Copper-binding data should therefore support mechanistic interpretation rather than serve as a standalone efficacy claim.

Evidence & Benchmarks

The following values are reported in the product dossier. The dossier does not provide one common assay temperature, buffer, pH, incubation time, or inoculum for all listed measurements. Values should therefore be reproduced under a validated, strain-specific method rather than compared as interchangeable constants.

• KR-12 is reported at a minimum inhibitory concentration of 64 μM against Escherichia coli K12 under the respective product-dossier assay conditions, which are not further specified in the supplied information product information
• KR-12 is reported at 2.1 μg/mL against Escherichia coli ATCC25922 under the respective product-dossier assay conditions, which are not further specified in the supplied information product information
• KR-12 is reported at 5 μg/mL against Candida albicans under the respective product-dossier assay conditions, which are not further specified in the supplied information product information
• KR-12 is reported at 8.4 μg/mL against Staphylococcus aureus under the respective product-dossier assay conditions, which are not further specified in the supplied information product information
• KR-12 is reported at 128–256 μg/mL against multidrug-resistant Acinetobacter baumannii under the respective product-dossier assay conditions, which are not further specified in the supplied information product information
• The cited LL-37-fragment literature reports KR-12 activity against E. coli at 40 μM under the assay conditions described in that publication, while the supplied excerpt does not reproduce the full experimental protocol 2024 reference study

The product dossier also reports no mammalian-cell toxicity up to 128 μg/mL under its stated but unspecified test conditions product information. The cited literature separately reports no human-cell cytotoxicity through 100 μg/mL, equivalent to approximately 63 μM, under the conditions of the referenced study 2024 reference study. These findings support comparative testing, not a universal therapeutic safety margin.

Applications, Limits & Misconceptions

The dossier describes anti-biofilm, LPS-neutralizing, anti-inflammatory, immunomodulatory, osteogenic, and wound-healing activities in addition to antimicrobial activity product information. Accordingly, investigators may evaluate this material as a KR-12 peptide anti-biofilm agent, KR-12 LPS-neutralizing peptide, KR-12 anti-inflammatory peptide, or KR-12 immunomodulatory peptide. Each application requires its own endpoint. A planktonic MIC does not measure biofilm prevention, LPS neutralization, cytokine modulation, bone differentiation, or wound closure.

Potential uses include bacterial membrane studies, comparative LL-37-fragment experiments, biofilm assays, endotoxin-response experiments, and exploratory infection-model work. The product description identifies potential utility in animal infection models, but that statement does not demonstrate efficacy, pharmacokinetics, tolerability, or regulatory readiness in humans product information.

Why this cross-domain matters, maturity, and limitations

Linking antimicrobial activity with inflammation, wound repair, or osteogenic activity is biologically relevant because infection and tissue injury can coexist. However, these domains use different experimental endpoints and controls. The cross-domain claims in this article are product-dossier descriptions, not conclusions from the Cu(II)-focused 2024 study. A mature evaluation should independently measure microbial burden, host-cell viability, inflammatory mediators, matrix or bone-associated endpoints, and wound closure in appropriately matched models.

Common Pitfalls or Misconceptions

• Misconception: KR-12 is automatically broad-spectrum. The listed results cover selected organisms and show a higher reported concentration range for multidrug-resistant A. baumannii than for several other organisms product information.
• Misconception: MIC values are universal peptide constants. MIC values depend on strain identity and assay conditions. The supplied dossier does not standardize the temperature, medium, pH, or incubation time across its numerical examples.
• Misconception: low reported mammalian toxicity proves clinical safety. Cell-based tolerance at a tested concentration does not establish tissue distribution, immunogenicity, dose tolerance, or efficacy in humans.
• Misconception: Cu(II) binding proves copper-dependent antimicrobial action. The 2024 study resolves coordination features but does not establish that Cu(II) is required for antibacterial activity in vivo 2024 reference study.
• Misconception: a TFA salt is identical to a free peptide in every calculation. Salt form, counterion content, concentration basis, and reconstitution conditions must be recorded when comparing experiments.

Workflow Integration & Parameters

Use KR-12 as a characterized research reagent. Record salt form, lot, peptide concentration basis, organism or cell system, assay medium, and endpoint. This metadata is essential when comparing molar and mass-based results.

Protocol Parameters

• Material identity: The C8754 product is KR-12 (human) TFA, sequence KRIVQRIKDFLR, CAS 1218951-51-9, and molecular weight 1684.97 Da; verify these fields before preparing an assay product specifications.
• Storage: Store the supplied material at −20 °C as directed by the product information. Protect the dry material from avoidable temperature excursions during handling storage guidance.
• Solution handling: Prepare solutions only when needed for the planned experiment. The product information does not recommend long-term storage of solutions, so use freshly prepared material promptly handling guidance.
• Antimicrobial assay: Determine MIC separately for each strain using the laboratory’s validated broth or agar method. Report temperature, pH, medium, inoculum, incubation duration, endpoint, and whether concentrations are expressed as μM or μg/mL.
• Mechanism controls: Pair growth inhibition with a membrane-integrity or membrane-association readout when testing the lipid-clustering and perforation model. Treat this as a workflow recommendation, not as a replacement for the product-dossier benchmarks.
• Cu(II) experiments: Record metal-ion concentration, buffer composition, pH, temperature, titration design, and peptide-to-metal ratio. The cited study used potentiometric, calorimetric, and theoretical approaches, but its coordination findings do not define a universal assay recipe 2024 reference study.

Related reading

KR-12 Peptide–Cu(II) Interactions: Insights from Theoretical Analysis emphasizes the metal-binding study; this article extends it by connecting coordination chemistry with product identity, antimicrobial benchmarks, and experimental boundaries.

KR-12 Human Peptide Attenuates Colitis via Anti-Inflammatory Actions focuses on an inflammation model; this article clarifies that anti-inflammatory positioning must remain distinct from direct MIC evidence.

KR-12 Human Antimicrobial Peptide: Applied Protocols & Innovations presents application-oriented workflows; this article adds explicit assay-condition caveats and a Cu(II) mechanistic boundary.

Conclusion & Outlook

KR-12 is a compact human LL-37-derived antimicrobial peptide with a defined sequence, a membrane-disruption rationale, and reported activity against selected microbial targets. Its Cu(II) interaction is supported by complementary theoretical and experimental analysis, with Asp26, Arg29, and backbone oxygen atoms implicated in coordination 2024 reference study.

The strongest next step is disciplined comparison. Researchers should reproduce organism-specific MIC values under fully reported conditions, separate planktonic from biofilm endpoints, and test host-cell responses independently. The same evidence supports KR-12 as a focused antimicrobial research reagent and a candidate for broader mechanistic studies, but it does not establish clinical efficacy or a universal safety threshold.